Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

Giacoppo S, Mazzon E.

Neural Regen Res. 2016 Dec;11(12):1896-1899. doi: 10.4103/1673-5374.197125. Review.

2.

Dendritic Cell Regulation by Cannabinoid-Based Drugs.

Svensson M, Chen P, Hammarfjord O.

Pharmaceuticals (Basel). 2010 Aug 23;3(8):2733-2750. Review.

3.

Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Bedlack RS, Joyce N, Carter GT, Paganoni S, Karam C.

Neurol Clin. 2015 Nov;33(4):909-36. doi: 10.1016/j.ncl.2015.07.008. Epub 2015 Sep 8. Review.

4.

An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's Disease.

de Paula CZ, Gonçalves BD, Vieira LB.

Biomed Res Int. 2015;2015:198612. doi: 10.1155/2015/198612. Epub 2015 Jul 29. Review.

5.

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Fernández-Ruiz J, Moro MA, Martínez-Orgado J.

Neurotherapeutics. 2015 Oct;12(4):793-806. doi: 10.1007/s13311-015-0381-7. Review.

6.

Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Karam CY, Paganoni S, Joyce N, Carter GT, Bedlack R.

Am J Hosp Palliat Care. 2016 Feb;33(1):84-92. doi: 10.1177/1049909114548719. Epub 2014 Sep 8. Review.

7.

ALS and oxidative stress: the neurovascular scenario.

Anand A, Thakur K, Gupta PK.

Oxid Med Cell Longev. 2013;2013:635831. doi: 10.1155/2013/635831. Epub 2013 Dec 3. Review.

8.

The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Scotter EL, Abood ME, Glass M.

Br J Pharmacol. 2010 Jun;160(3):480-98. doi: 10.1111/j.1476-5381.2010.00735.x. Review.

9.

Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.

Basavarajappa BS, Nixon RA, Arancio O.

Mini Rev Med Chem. 2009 Apr;9(4):448-62. Review.

10.

Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Cabral GA, Griffin-Thomas L.

Expert Rev Mol Med. 2009 Jan 20;11:e3. doi: 10.1017/S1462399409000957. Review.

11.

Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Cabral GA, Griffin-Thomas L.

Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):159-72. Review.

12.

Cannabinoids in health and disease.

Kogan NM, Mechoulam R.

Dialogues Clin Neurosci. 2007;9(4):413-30. Review.

13.

Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.

Zhao P, Ignacio S, Beattie EC, Abood ME.

Eur J Neurosci. 2008 Feb;27(3):572-9. doi: 10.1111/j.1460-9568.2008.06041.x.

14.

Dosing medical marijuana: rational guidelines on trial in Washington State.

Aggarwal SK, Kyashna-Tocha M, Carter GT.

MedGenMed. 2007 Sep 11;9(3):52. No abstract available.

15.

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL.

J Neurochem. 2007 Apr;101(1):87-98. Epub 2007 Jan 4.

Supplemental Content

Support Center